New drug combo shrinks tumors before surgery in early trial
NCT ID NCT04481113
First seen Jan 30, 2026 · Last updated Jun 10, 2026 · Updated 21 times
Summary
This early-phase study tested the safety and best dose of two drugs, abemaciclib and niraparib, given together before surgery for a common type of breast cancer (HR+ HER2-). The goal was to see if the combination could shrink tumors before they are removed. Only 8 people took part, and the main focus was on side effects and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.